Key value drivers

Therapeutics: AfaSci has developed three very interesting drug candidate series:

Technology: AfaSci's SmartCagetm system performs 10 automated behavioral assays, resulting in increased throughput and quality while reducing costs for in vivo behavioral phenotyping, drug screening, and pharmacology.

Our competitive advantages include:

  • novel drug candidates ready for IND-enabling studies
  • proprietary technologies
  • in-house research capacity in electrophysiology
  • in vivo pharmacology.

AfaSci employs a highly productive research team with complementary skill sets, and enjoys broad academic collaborations.